IL1B and type 2 diabetes mellitus: Similar findings have been shown in BTBR ob/ob T2DM mice, where dapagliflozin reduced the activation of the NLRP3/ASC inflammasome and cardiac levels of IL-1β, IL-6, and TNF-α [45].